Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.

dc.contributor.authorBooth, David R.cat
dc.contributor.authorTan, Si-Yencat
dc.contributor.authorBooth, Sussanne E.cat
dc.contributor.authorTennent, Glenys A.cat
dc.contributor.authorHutchinson, Winston L.cat
dc.contributor.authorHsuan, J. Justincat
dc.contributor.authorTotty, Nicholas F.cat
dc.contributor.authorTruong, Oanhcat
dc.contributor.authorSoutar, Anne K.cat
dc.contributor.authorHawkins, Philip N.cat
dc.contributor.authorBruguera i Cortada, Miquel, 1942-cat
dc.contributor.authorCaballeria Rovira, Joancat
dc.contributor.authorSolé, Manelcat
dc.contributor.authorCampistol Plana, Josep M.cat
dc.contributor.authorPepys, Mark B.cat
dc.date.accessioned2009-05-15T08:23:06Z
dc.date.available2009-05-15T08:23:06Z
dc.date.issued1996cat
dc.description.abstractWe report a Spanish family with autosomal-dominant non-neuropathic hereditary amyloidosis with a unique hepatic presentation and death from liver failure, usually by the sixth decade. The disease is caused by a previously unreported deletion/insertion mutation in exon 4 of the apolipoprotein AI (apoAI) gene encoding loss of residues 60-71 of normal mature apoAI and insertion at that position of two new residues, ValThr. Affected individuals are heterozygous for this mutation and have both normal apoAI and variant molecules bearing one extra positive charge, as predicted from the DNA sequence. The amyloid fibrils are composed exclusively of NH2-terminal fragments of the variant, ending mainly at positions corresponding to residues 83 and 92 in the mature wild-type sequence. Amyloid fibrils derived from the other three known amyloidogenic apoAI variants are also composed of similar NH2-terminal fragments. All known amyloidogenic apoAI variants carry one extra positive charge in this region, suggesting that it may be responsible for their enhanced amyloidogenicity. In addition to causing a new phenotype, this is the first deletion mutation to be described in association with hereditary amyloidosis and it significantly extends the value of the apoAI model for investigation of molecular mechanisms of amyloid fibrillogenesis.eng
dc.format.extent8 p.cat
dc.format.mimetypeapplication/pdfeng
dc.identifier.idgrec122436cat
dc.identifier.issn0021-9738cat
dc.identifier.pmid8675681
dc.identifier.urihttps://hdl.handle.net/2445/8305
dc.language.isoengeng
dc.publisherAmerican Society for Clinical Investigationcat
dc.relation.isformatofReproducció del document publicat a http://dx.doi.org/10.1172/JCI118725cat
dc.relation.ispartofJournal of Clinical Investigation, 1996, vol. 97, núm. 12, p. 2714¿2721.cat
dc.relation.urihttp://dx.doi.org/10.1172/JCI118725
dc.rights(c) The American Society for Clinical Investigation, 1996cat
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationAmiloïdosicat
dc.subject.classificationProteïnescat
dc.subject.classificationFetgecat
dc.subject.classificationGenètica molecularcat
dc.subject.otherAmyloidosiseng
dc.subject.otherApolipoprotein AIeng
dc.subject.otherGeneeng
dc.subject.otherLivereng
dc.subject.otherMutationeng
dc.titleHereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.eng
dc.typeinfo:eu-repo/semantics/articleeng
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
122436.pdf
Mida:
378.31 KB
Format:
Adobe Portable Document Format